Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 1
2010 3
2011 1
2018 1
2019 1
2020 3
2021 2
2022 1
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, Wang B, Wu Q, Ramos I, Pawashe A, Canova L, Vazzana K, Ram P, Herlihy E, Ahmed H, Oswald E, Golubov J, Poon P, Havel L, Chiu D, Lazo M, Provoncha K, Yu K, Kim J, Warsaw JJ, Stokes Oristian N, Siao CJ, Dudgeon D, Huang T, Potocky T, Martin J, MacDonald D, Oyejide A, Rafique A, Poueymirou W, Kirshner JR, Smith E, Olson W, Lin J, Thurston G, Sleeman MA, Murphy AJ, Yancopoulos GD. Skokos D, et al. Among authors: dudgeon d. Sci Transl Med. 2020 Jan 8;12(525):eaaw7888. doi: 10.1126/scitranslmed.aaw7888. Sci Transl Med. 2020. PMID: 31915305
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Ahmed H, Kamat V, Dorvilliers A, Navarro E, Xiao J, Kim J, Yang SN, Warsaw J, Lett C, Canova L, Schulenburg T, Foster R, Krueger P, Garnova E, Rafique A, Babb R, Chen G, Stokes Oristian N, Siao CJ, Daly C, Gurer C, Martin J, Macdonald L, MacDonald D, Poueymirou W, Smith E, Lowy I, Thurston G, Olson W, Lin JC, Sleeman MA, Yancopoulos GD, Murphy AJ, Skokos D. Waite JC, et al. Among authors: dudgeon d. Sci Transl Med. 2020 Jun 24;12(549):eaba2325. doi: 10.1126/scitranslmed.aba2325. Sci Transl Med. 2020. PMID: 32581132
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Wu J, Bloch N, Chang AY, Bhavsar R, Wang Q, Crawford A, DiLillo DJ, Vazzana K, Mohrs K, Dudgeon D, Patel S, Ahmed H, Garg V, Amatulli M, Antao OQ, Yan Y, Wang S, Ramos W, Krueger P, Adler C, Ni M, Wei Y, Guo C, Macdonald L, Huang T, Ullman E, Hermann A, Yancopoulos GD, Murphy AJ, Davis S, Olson WC, Lin JC, Smith E, Zhang T. Wu J, et al. Among authors: dudgeon d. Cell Rep Med. 2024 Oct 15;5(10):101747. doi: 10.1016/j.xcrm.2024.101747. Epub 2024 Sep 25. Cell Rep Med. 2024. PMID: 39326410 Free PMC article.
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Haber L, et al. Among authors: dudgeon d. Sci Rep. 2021 Jul 13;11(1):14397. doi: 10.1038/s41598-021-93842-0. Sci Rep. 2021. PMID: 34257348 Free PMC article.
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054.
Tavaré R, Danton M, Giurleo JT, Makonnen S, Hickey C, Arnold TC, Kelly MP, Fredriksson F, Bruestle K, Hermann A, Ullman E, Edelmann KH, Potocky T, Dudgeon D, Bhatt NB, Doubrovin M, Barry T, Kyratsous CA, Gurer C, Tu N, Gartner H, Murphy A, Macdonald LE, Popke J, Mintz A, Griesemer A, Olson WC, Thurston G, Ma D, Kirshner JR. Tavaré R, et al. Among authors: dudgeon d. Cancer Immunol Res. 2022 Oct 4;10(10):1190-1209. doi: 10.1158/2326-6066.CIR-21-0405. Cancer Immunol Res. 2022. PMID: 35895745 Free PMC article.
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
Yang Y, Suhasini AN, Jiang Z, Liu N, Rosconi M, Zhang B, Li Y, Dudgeon D, Seong C, Kim S, Rafique A, Huang T, Bhosle S, Krueger P, Ullman E, Olson W, Lin JC, Shen Y, Daly C. Yang Y, et al. Among authors: dudgeon d. Cancer Res. 2024 Jul 2;84(13):2169-2180. doi: 10.1158/0008-5472.CAN-23-3195. Cancer Res. 2024. PMID: 39082679 Free PMC article.
Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.
Kelly MP, Makonnen S, Hickey C, Arnold TC, Giurleo JT, Tavaré R, Danton M, Granados C, Chatterjee I, Dudgeon D, Retter MW, Ma D, Olson WC, Thurston G, Kirshner JR. Kelly MP, et al. Among authors: dudgeon d. J Immunother Cancer. 2021 Jan;9(1):e002025. doi: 10.1136/jitc-2020-002025. J Immunother Cancer. 2021. PMID: 33483343 Free PMC article.
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates.
Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA. Pascal KE, et al. Among authors: dudgeon d. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285. J Infect Dis. 2018. PMID: 29860496 Free PMC article.
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
DaSilva JO, Yang K, Perez Bay AE, Andreev J, Ngoi P, Pyles E, Franklin MC, Dudgeon D, Rafique A, Dore A, Delfino FJ, Potocky TB, Babb R, Chen G, MacDonald D, Olson WC, Thurston G, Daly C. DaSilva JO, et al. Among authors: dudgeon d. Clin Cancer Res. 2020 Mar 15;26(6):1408-1419. doi: 10.1158/1078-0432.CCR-19-2428. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848185
17 results